Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Par Pharmaceutical Companies has announced that the US District Court of New Jersey has granted AstraZeneca Pharmaceuticals's motion for a temporary restraining order halting sales of Teva's generic Pulmicort Respules.
Subscribe to our email newsletter
In conjunction with the court’s order against Teva, AstraZeneca agreed that it too would halt all sales of its authorized generic budesonide inhalation suspension product and take other necessary steps to comply with the court’s decision.
Par is the licensed distributor for AstraZeneca’s authorized generic version of Pulmicort Respules.
The temporary restraining order remains in force until further notice by the court. This action does not effect sales of branded Pulmicort Respules, said Par.